Benchling, a San Francisco, CA-based provider of an R&D Cloud for the biotechnology industry, raised $100m in Series F funding, at a $6.1 billion valuation.
The round was co-led by new investor Franklin Templeton and existing investor Altimeter Capital, and joined by new investors Tiger Global and Lone Pine Capital, as well as existing investors.
The company will use the funding to continue investing in product development and global expansion, particularly its presence in EMEA.
Led by Sajith Wickramasekara, CEO, Benchling provides R&D Cloud, which is a software platform that powers the biotechnology industry. More than 200,000 scientists at over 600 companies and 7,000 research institutions globally have adopted the company’s R&D Cloud to make discoveries and bring the next generation of medicines, food, and materials to market.
Since announcing its Series E raise in April, the company has introduced new capabilities and solutions, including support for Early Development and RNA therapeutics. The company also hired Salesforce executive Lindsey Irvine as Chief Marketing Officer. In just one year since entering the EMEA market, Benchling has reached over 90 customers in Europe, including Cutiss AG, Sanofi, Selexis SA, and Syngenta, and grown its European team to over 60 people.